TGFB1 and renal fibrosis: The oral administration of the PPAR-γ agonist pioglitazone significantly attenuated TGF-β1-induced renal fibrosis by suppressing the activation of early growth response factor-1 (EGR-1), STAT3, and AP-1, thereby exerting a protective effect on kidney health [228].